RU2010123781A - Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли - Google Patents
Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли Download PDFInfo
- Publication number
- RU2010123781A RU2010123781A RU2010123781/04A RU2010123781A RU2010123781A RU 2010123781 A RU2010123781 A RU 2010123781A RU 2010123781/04 A RU2010123781/04 A RU 2010123781/04A RU 2010123781 A RU2010123781 A RU 2010123781A RU 2010123781 A RU2010123781 A RU 2010123781A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- aliphatic group
- compound according
- compound
- acute
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 33
- 102000004310 Ion Channels Human genes 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 claims abstract 34
- 230000036407 pain Effects 0.000 claims abstract 29
- 238000000034 method Methods 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 125000001931 aliphatic group Chemical group 0.000 claims 19
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 208000004296 neuralgia Diseases 0.000 claims 7
- 206010019233 Headaches Diseases 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000005298 acute pain Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 231100000869 headache Toxicity 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000002981 neuropathic effect Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 150000004867 thiadiazoles Chemical group 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 201000001969 Achilles bursitis Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 201000011384 erythromelalgia Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 210000004705 lumbosacral region Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 210000000689 upper leg Anatomy 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- MKLARCZMDNIPPA-UHFFFAOYSA-N benzenesulfonamide;pyrrolidin-2-one Chemical class O=C1CCCN1.NS(=O)(=O)C1=CC=CC=C1 MKLARCZMDNIPPA-UHFFFAOYSA-N 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 0 CC(CCCN(C1)C(CCN2c(cc3)ccc3S(NC3CCCCCCCCC3)(=O)=O)*2=O)C1c1cc(*)c(*)c(*)c1 Chemical compound CC(CCCN(C1)C(CCN2c(cc3)ccc3S(NC3CCCCCCCCC3)(=O)=O)*2=O)C1c1cc(*)c(*)c(*)c1 0.000 description 2
- RWQAGKGHFCSUJO-SFTDATJTSA-N O=C([C@H](CC1)N2C[C@@H](c3cc(Cl)cc(Cl)c3)OCC2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N2C[C@@H](c3cc(Cl)cc(Cl)c3)OCC2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O RWQAGKGHFCSUJO-SFTDATJTSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98748507P | 2007-11-13 | 2007-11-13 | |
| US60/987,485 | 2007-11-13 | ||
| US8814108P | 2008-08-12 | 2008-08-12 | |
| US61/088,141 | 2008-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010123781A true RU2010123781A (ru) | 2011-12-20 |
Family
ID=40380263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010123781/04A RU2010123781A (ru) | 2007-11-13 | 2008-11-12 | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7994166B2 (enExample) |
| EP (1) | EP2231655B1 (enExample) |
| JP (1) | JP2011503112A (enExample) |
| KR (1) | KR20100098396A (enExample) |
| CN (1) | CN102036985A (enExample) |
| AT (1) | ATE522526T1 (enExample) |
| AU (1) | AU2008321137A1 (enExample) |
| CA (1) | CA2705336A1 (enExample) |
| IL (1) | IL205697A0 (enExample) |
| MX (1) | MX2010005309A (enExample) |
| NZ (1) | NZ585332A (enExample) |
| RU (1) | RU2010123781A (enExample) |
| WO (1) | WO2009064747A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| ZA200802977B (en) * | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| AU2008321142A1 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| EP2307412A2 (en) * | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2013109521A1 (en) * | 2012-01-16 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
| WO2014056958A1 (en) | 2012-10-12 | 2014-04-17 | F. Hoffmann-La Roche Ag | Substituted phenylcarbamate compounds |
| WO2014060341A1 (en) | 2012-10-16 | 2014-04-24 | F. Hoffmann-La Roche Ag | Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| US10968210B2 (en) | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR20200030584A (ko) | 2017-07-21 | 2020-03-20 | 앤타바이오 에스에이에스 | 화합물 |
| CN113008999B (zh) * | 2019-12-19 | 2024-08-23 | 重庆药友制药有限责任公司 | 一种分离测定氟比洛芬酯中2种基因毒性杂质的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU2004240885A1 (en) * | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2007261945A (ja) * | 2004-04-07 | 2007-10-11 | Taisho Pharmaceut Co Ltd | チアゾール誘導体 |
| CN101218235A (zh) | 2005-05-10 | 2008-07-09 | 沃泰克斯药物股份有限公司 | 作为离子通道调控剂的二环衍生物 |
| EP1888558B1 (en) * | 2005-05-16 | 2011-10-05 | Vertex Pharmaceuticals, Inc. | Bicyclic derivatives as modulators of ion channels |
| EP1891039A1 (en) | 2005-05-20 | 2008-02-27 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
| WO2006133459A1 (en) * | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| ZA200802977B (en) | 2005-09-09 | 2009-08-26 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| US7683083B2 (en) | 2005-10-12 | 2010-03-23 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| WO2007075895A2 (en) * | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| CA2687764A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| CN102036985A (zh) | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| AU2008321142A1 (en) * | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| EP2307412A2 (en) | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
-
2008
- 2008-11-12 CN CN2008801225096A patent/CN102036985A/zh active Pending
- 2008-11-12 RU RU2010123781/04A patent/RU2010123781A/ru not_active Application Discontinuation
- 2008-11-12 CA CA2705336A patent/CA2705336A1/en not_active Abandoned
- 2008-11-12 AU AU2008321137A patent/AU2008321137A1/en not_active Abandoned
- 2008-11-12 NZ NZ585332A patent/NZ585332A/en not_active IP Right Cessation
- 2008-11-12 WO PCT/US2008/083165 patent/WO2009064747A2/en not_active Ceased
- 2008-11-12 KR KR1020107012968A patent/KR20100098396A/ko not_active Withdrawn
- 2008-11-12 AT AT08850039T patent/ATE522526T1/de active
- 2008-11-12 JP JP2010533335A patent/JP2011503112A/ja not_active Withdrawn
- 2008-11-12 EP EP08850039A patent/EP2231655B1/en not_active Not-in-force
- 2008-11-12 MX MX2010005309A patent/MX2010005309A/es active IP Right Grant
- 2008-11-12 US US12/269,108 patent/US7994166B2/en not_active Expired - Fee Related
-
2010
- 2010-05-11 IL IL205697A patent/IL205697A0/en unknown
-
2011
- 2011-07-08 US US13/178,877 patent/US20120010416A1/en not_active Abandoned
-
2013
- 2013-08-15 US US13/967,732 patent/US8841282B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE522526T1 (de) | 2011-09-15 |
| EP2231655A2 (en) | 2010-09-29 |
| MX2010005309A (es) | 2010-06-25 |
| WO2009064747A2 (en) | 2009-05-22 |
| US20120010416A1 (en) | 2012-01-12 |
| CN102036985A (zh) | 2011-04-27 |
| US20130338119A1 (en) | 2013-12-19 |
| JP2011503112A (ja) | 2011-01-27 |
| IL205697A0 (en) | 2010-11-30 |
| AU2008321137A1 (en) | 2009-05-22 |
| US7994166B2 (en) | 2011-08-09 |
| WO2009064747A3 (en) | 2010-08-19 |
| CA2705336A1 (en) | 2009-05-22 |
| KR20100098396A (ko) | 2010-09-06 |
| NZ585332A (en) | 2012-05-25 |
| US20090131440A1 (en) | 2009-05-21 |
| EP2231655B1 (en) | 2011-08-31 |
| US8841282B2 (en) | 2014-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011103451A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2011503112A5 (enExample) | ||
| JP2011526919A5 (enExample) | ||
| JP7607732B2 (ja) | 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法 | |
| JP2010539244A5 (enExample) | ||
| JP2010528035A5 (enExample) | ||
| JP2011503191A5 (enExample) | ||
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| DK2598482T3 (en) | ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | |
| EA034759B1 (ru) | Пролекарства рилузола и их применение | |
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| RU2016125705A (ru) | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов | |
| WO2012045883A1 (en) | Cyclopropylamine inhibitors of oxidases | |
| MY139399A (en) | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| US20120283266A1 (en) | Lysine specific demethylase-1 inhibitors and their use | |
| RU2492163C9 (ru) | Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии | |
| DE60235396D1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
| WO2012112674A2 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
| CA2471974A1 (en) | Quinazolinone derivatives and their use as cb agonists | |
| JP2018520158A (ja) | 疾患を処置するためのｇｌｓ１阻害薬 | |
| RU2012109220A (ru) | Новые соединения и их терапевтическое использование для ингибирования протеинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20121022 |